CreativeOne Wealth LLC Invests $203,000 in Exelixis, Inc. (NASDAQ:EXEL)

CreativeOne Wealth LLC bought a new position in Exelixis, Inc. (NASDAQ:EXEL) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 7,837 shares of the biotechnology company’s stock, valued at approximately $203,000.

Several other hedge funds also recently made changes to their positions in the company. Covestor Ltd increased its holdings in shares of Exelixis by 5.7% in the 3rd quarter. Covestor Ltd now owns 6,335 shares of the biotechnology company’s stock valued at $164,000 after purchasing an additional 341 shares in the last quarter. Resonant Capital Advisors LLC increased its holdings in shares of Exelixis by 3.6% in the 2nd quarter. Resonant Capital Advisors LLC now owns 13,746 shares of the biotechnology company’s stock valued at $309,000 after purchasing an additional 477 shares in the last quarter. Cornercap Investment Counsel Inc. increased its holdings in shares of Exelixis by 1.1% in the 2nd quarter. Cornercap Investment Counsel Inc. now owns 50,497 shares of the biotechnology company’s stock valued at $1,135,000 after purchasing an additional 539 shares in the last quarter. Creative Planning increased its holdings in shares of Exelixis by 0.8% in the 2nd quarter. Creative Planning now owns 71,700 shares of the biotechnology company’s stock valued at $1,611,000 after purchasing an additional 548 shares in the last quarter. Finally, Advisors Asset Management Inc. increased its holdings in shares of Exelixis by 3.2% in the 3rd quarter. Advisors Asset Management Inc. now owns 19,853 shares of the biotechnology company’s stock valued at $515,000 after purchasing an additional 609 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Stock Down 0.9 %

Shares of EXEL stock opened at $35.26 on Wednesday. The stock has a market cap of $10.07 billion, a price-to-earnings ratio of 22.60, a price-to-earnings-growth ratio of 0.90 and a beta of 0.52. Exelixis, Inc. has a fifty-two week low of $19.20 and a fifty-two week high of $36.97. The firm’s 50 day moving average price is $31.00 and its two-hundred day moving average price is $26.25.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.36 by $0.04. The company had revenue of $539.50 million for the quarter, compared to analyst estimates of $490.31 million. Exelixis had a net margin of 22.43% and a return on equity of 20.99%. The business’s quarterly revenue was up 14.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.10 earnings per share. On average, equities analysts forecast that Exelixis, Inc. will post 1.69 EPS for the current fiscal year.

Wall Street Analyst Weigh In

EXEL has been the subject of a number of research analyst reports. BMO Capital Markets increased their price target on shares of Exelixis from $29.00 to $36.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. HC Wainwright restated a “buy” rating and set a $29.00 target price on shares of Exelixis in a report on Wednesday, September 18th. Morgan Stanley raised their target price on shares of Exelixis from $26.00 to $28.00 and gave the company an “equal weight” rating in a report on Friday, October 11th. UBS Group began coverage on shares of Exelixis in a report on Thursday, September 19th. They set a “neutral” rating and a $30.00 target price for the company. Finally, Bank of America raised their target price on shares of Exelixis from $30.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, October 15th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $31.44.

Insider Buying and Selling

In related news, EVP Patrick J. Haley sold 41,588 shares of Exelixis stock in a transaction on Monday, November 18th. The shares were sold at an average price of $34.36, for a total value of $1,428,963.68. Following the completion of the sale, the executive vice president now owns 288,665 shares in the company, valued at approximately $9,918,529.40. The trade was a 12.59 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Dana Aftab sold 1,162 shares of Exelixis stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $31.40, for a total transaction of $36,486.80. Following the completion of the sale, the executive vice president now owns 498,945 shares of the company’s stock, valued at approximately $15,666,873. This trade represents a 0.23 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 339,736 shares of company stock worth $11,508,610. Insiders own 2.85% of the company’s stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.